sotalol trial summary

Immediate beta-blockers: 1 trials - Lloyd

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
All cause death	1.00 [0.02 53.89]	p=1.00	0	30	1	Lloyd ,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death or hospitalization for cardiac causes	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Atrial fibrillation recurrence	1.07 [0.53 2.14]	p=1.00	0	128	1	Plewan,
Cardiac nonarrhythmic death	no data
Cardiac arrhythmic death	no data
Vascular noncardiac death	no data
hospitalization for AF	no data
hospitalisation for heart failure	no data
Pro-arrhythmia	1.33 [0.29 6.21]	p=1.00	0	128	1	Plewan,
All cause death	1.00 [0.02 51.18]	p=1.00	0	128	1	Plewan,
non cardiovascular death	no data
Adverse events leading to treatment discontinuation	1.33 [0.29 6.21]	p=1.00	0	128	1	Plewan,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death or hospitalization for cardiac causes	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Atrial fibrillation recurrence	1.33 [0.36 4.94]	p=1.00	0	40	1	Carunchio (sotalol vs flecianide),
Cardiac nonarrhythmic death	no data
Cardiac arrhythmic death	no data
Vascular noncardiac death	no data
hospitalization for AF	no data
hospitalisation for heart failure	no data
Pro-arrhythmia	1.67 [0.34 8.18]	p=1.00	0	40	1	Carunchio (sotalol vs flecianide),
All cause death	1.00 [0.02 52.98]	p=1.00	0	40	1	Carunchio (sotalol vs flecianide),
non cardiovascular death	no data
Adverse events leading to treatment discontinuation	1.00 [0.02 52.98]	p=1.00	0	40	1	Carunchio (sotalol vs flecianide),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

suggested Pro-arrhythmia by 106% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death or hospitalization for cardiac causes	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Atrial fibrillation recurrence	0.79 [0.64 0.99]	p=0.04	0	2078	8	Benditt,Singh,Bellandi (sotalol vs placebo),Carunchio (sotalol vs placebo),Kochiadakis b (sotalol vs placebo),PAFAC (sotalol vs placebo),SAFE-T (sotalol vs placebo),SOPAT (sotalol vs placebo),
Cardiac nonarrhythmic death	no data
Cardiac arrhythmic death	no data
Vascular noncardiac death	no data
hospitalization for AF	no data
hospitalisation for heart failure	no data
Pro-arrhythmia	2.06 [1.05 4.04]	p=0.04	0	2078	8	Benditt,Singh,Bellandi (sotalol vs placebo),Carunchio (sotalol vs placebo),Kochiadakis b (sotalol vs placebo),PAFAC (sotalol vs placebo),SAFE-T (sotalol vs placebo),SOPAT (sotalol vs placebo),
All cause death	1.73 [0.76 3.90]	p=1.00	0	2078	8	Benditt,Singh,Bellandi (sotalol vs placebo),Carunchio (sotalol vs placebo),Kochiadakis b (sotalol vs placebo),PAFAC (sotalol vs placebo),SAFE-T (sotalol vs placebo),SOPAT (sotalol vs placebo),
non cardiovascular death	no data
Adverse events leading to treatment discontinuation	1.10 [0.80 1.51]	p=1.00	0	1685	7	Benditt,Singh,Bellandi (sotalol vs placebo),Carunchio (sotalol vs placebo),Kochiadakis b (sotalol vs placebo),PAFAC (sotalol vs placebo),SOPAT (sotalol vs placebo),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
death or hospitalization for cardiac causes	no data
cardiovascular events	no data
Cardiovascular death	no data
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Atrial fibrillation recurrence	1.24 [0.68 2.28]	p=1.00	0	171	1	Kochiadakis b (sotalol vs propafenome),
Cardiac nonarrhythmic death	no data
Cardiac arrhythmic death	no data
Vascular noncardiac death	no data
hospitalization for AF	no data
hospitalisation for heart failure	no data
Pro-arrhythmia	1.52 [0.25 9.32]	p=1.00	0	171	1	Kochiadakis b (sotalol vs propafenome),
All cause death	1.01 [0.02 51.58]	p=1.00	0	171	1	Kochiadakis b (sotalol vs propafenome),
non cardiovascular death	no data
Adverse events leading to treatment discontinuation	1.01 [0.28 3.63]	p=1.00	0	171	1	Kochiadakis b (sotalol vs propafenome),

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Sotalol beta-blockers